TET2 Clonal Hematopoiesis Identified as Biomarker for Enhanced Immunotherapy Response in Large-Scale Cancer Study
Key Insights
Caris Life Sciences (search) and MD Anderson Cancer Center researchers identified TET2 (search) clonal hematopoiesis as a promising biomarker for improved immune checkpoint inhibitor therapy response in solid tumors.
The study analyzed nearly 36,000 non-small cell lung cancer patients and over 25,000 colorectal cancer patients using Caris' extensive clinico-genomic database.
Laboratory models revealed that TET2 (search) mutations enhance macrophage antigen presentation and shape immune dynamics within the tumor microenvironment.
Caris Life Sciences (search) and researchers at The University of Texas MD Anderson Cancer Center have identified TET2 (search) clonal hematopoiesis (CH) as a promising biomarker for enhanced response to immune checkpoint inhibitor (ICI) therapy in patients with solid tumors. The collaborative research, published in Cancer Cell, analyzed outcomes in over 61,000 cancer patients and provides the first major evidence directly linking clonal hematopoiesis to therapy outcomes in solid tumors.
Large-Scale Clinical Validation
The study leveraged Caris Life Sciences (search)' extensive clinico-genomic database to validate clinical findings in a real-world cohort of nearly 36,000 patients with non-small cell lung cancer (NSCLC) and over 25,000 colorectal cancer patients. This large-scale analysis provided robust evidence supporting TET2 (search)-CH as a potential biomarker for enhanced ICI response.
The research was led by Padmanee Sharma, M.D., Ph.D. at the James P. Allison Institute at MD Anderson Cancer Center, with Shelley Herbrich, Ph.D., a postdoctoral fellow in Dr. Sharma's lab, contributing to the mechanistic investigations.
Mechanistic Insights from Laboratory Models
The study investigated how immune cells carrying CH-derived TET2 (search) mutations influence solid tumor immunology and respond to ICI therapy. Using TET2-mutant laboratory models, researchers revealed how these mutations shape immune dynamics within the tumor microenvironment, specifically enhancing macrophage antigen presentation.
"These findings represent a major step forward in understanding how clonal hematopoiesis influences cancer immunology," said Milan Radovich, Ph.D., Senior Vice President and Chief Scientific Officer at Caris. "It further demonstrates that we are only scratching the surface on the potential applications of CH, namely a novel function of CH as a predictive therapeutic biomarker that can be used to improve patient outcomes."
Clinical Implications for Therapy Selection
The dual approach of mechanistic laboratory studies combined with large-scale clinical validation provided insight and evidence supporting TET2 (search)-CH as a potential biomarker for enhanced ICI response. These findings represent a major observation that directly ties clonal hematopoiesis to therapy outcomes in solid tumors, suggesting a future role of CH for driving therapy selection.
"These results are encouraging, highlighting TET2 (search)-mutated clonal hematopoiesis as a potential biomarker to select patients who are more likely to respond to immunotherapy," said Dr. Sharma, who is professor of Immunology and Genitourinary Medical Oncology at MD Anderson and director of scientific programs for the Allison Institute.
Precision Medicine Applications
The research utilized Caris Life Sciences (search)' comprehensive molecular profiling capabilities, including Whole Exome and Whole Transcriptome Sequencing, combined with advanced AI and machine learning algorithms. This approach enabled the analysis of the large-scale, multimodal clinico-genomic database necessary to unravel the molecular complexity of the relationship between clonal hematopoiesis and immunotherapy response.
The study's findings suggest that TET2 (search)-CH could serve as a predictive therapeutic biomarker to improve patient outcomes by identifying those most likely to benefit from immune checkpoint inhibitor therapy. This represents a significant advancement in precision oncology, potentially enabling more targeted and effective treatment strategies for patients with solid tumors.